NHS Framework Agreement for Branded Medicines, Cytokine Modulators, Monoclonal Antibodies, and Fondaparinux in North of England

About

NHS England awarded a contract to ACRE PHARMA LIMITED, AMGEN LIMITED, ASPEN PHARMA LTD, ASTELLAS PHARMA LTD., SANOFI-AVENTIS UK HOLDINGS LIMITED, BAYER PUBLIC LIMITED COMPANY, BIOGEN LTD, BRISTOL-MYERS SQUIBB PHARMACEUTICALS LIMITED, and CELLTRIO for the supply of branded medicines, cytokine modulators, other monoclonal antibodies, and Fondaparinux under a framework agreement for the NHS North of England Region.

The contract value is £205,535,556.

The framework includes multiple tranches: Tranche B for branded medicines from 1 March 2020 to 28 February 2022 with an option to extend up to 24 months; an annual tranche for cytokine modulators and monoclonal antibodies from 1 March 2020 to 28 February 2021 with an option to extend up to 12 months; and Fondaparinux supply for London from 1 March 2020 to 31 August 2021, South of England from 1 March 2020 to 31 August 2020, and Midlands and East from 1 March 2020 to 28 February 2021, each with extension options up to 24 months.